These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 8558517)

  • 1. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
    J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
    Curtin ML; Davidsen SK; Heyman HR; Garland RB; Sheppard GS; Florjancic AS; Xu L; Carrera GM; Steinman DH; Trautmann JA; Albert DH; Magoc TJ; Tapang P; Rhein DA; Conway RG; Luo G; Denissen JF; Marsh KC; Morgan DW; Summers JB
    J Med Chem; 1998 Jan; 41(1):74-95. PubMed ID: 9438024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
    Carceller E; Merlos M; Giral M; Almansa C; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1993 Oct; 36(20):2984-97. PubMed ID: 8411016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH
    J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
    Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
    Carceller E; Salas J; Merlos M; Giral M; Ferrando R; Escamilla I; Ramis J; García-Rafanell J; Forn J
    J Med Chem; 2001 Aug; 44(18):3001-13. PubMed ID: 11520209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
    J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Cooper K; Parry MJ; Richardson K; Steele J
    J Med Chem; 1995 Sep; 38(18):3514-23. PubMed ID: 7658438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo.
    Alabaster VA; Keir RF; Parry MJ; de Souza RN
    Agents Actions Suppl; 1991; 34():221-7. PubMed ID: 1793066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
    Dickinson RP; Dack KN; Long CJ; Steele J
    J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
    Balsa D; Merlos M; Giral M; Ferrando R; Garcia-Rafanell J; Forn J
    Drugs Exp Clin Res; 1997; 23(5-6):191-9. PubMed ID: 9515229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y; Imanishi N; Uchida M; Morooka S
    Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N; Martin M; Bensaid O; Cisternino S; Rousselle C; Dereuddre-Bosquet N; Huet J; Redeuilh C; Lamouri A; Dong CZ; Clayette P; Scherrmann JM; Dormont D; Heymans F
    J Med Chem; 2004 Dec; 47(25):6410-9. PubMed ID: 15566310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP; Schmidt B; Ostermann G
    Pharmazie; 1992 Mar; 47(3):172-4. PubMed ID: 1615020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.